Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from January 10, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on April 10, 2026.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$56.00 – $59.00Entry zone — fair-value band

$58.81Published — price the day we called it

$64.69Target — the price the thesis aimed for

$64.16Peak — highest point inside the window, not a realized return

$37.52Window close — end-of-window price, context only

What happened

Target reached

Hit or exceeded the predicted growth inside the window.

Peak price

$64.16

peak on January 23, 2026 — not a realized return

Peak gain

+9.1%

peak, from the publication price

Window close

$37.52

end-of-window price, context only

Days to target

—

Window

January 10, 2026 – April 10, 2026

The thesis — published January 10, 2026

Predicted growth

+10%

over the measurement window

Target price

$64.69

the price the thesis aimed for

Entry zone

$56.00 – $59.00

the fair-value band we waited for

Price at publication

$58.81

published January 10, 2026

Confidence

62%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk is a leader in obesity treatments and just got wider access through a major pharmacy listing. The stock has moved up a lot recently, so it may be safer to wait for a short-term drop before buying. If pricing or insurance news changes suddenly, the share price could fall quickly, so buy in smaller amounts after a pullback and confirmation.

Primary drivers

Major pharmacy now offers Wegovy, improving access and awareness
Strong, persistent demand for obesity treatments
Adds stability by diversifying a healthcare portfolio
Price or insurance news could quickly change the outlook

How it played out

NVO: peak stayed below target, then shares fell

Lyra published NVO on 2026-01-10 at $58.81 for a short-term window ending 2026-04-10. The thesis expected 10% growth toward $64.69. It pointed to wider Wegovy access through a major pharmacy listing, strong demand for obesity treatments, portfolio stability from healthcare exposure, and the risk that price or insurance news could change the outlook quickly.

The stock rose early and peaked at $64.16 on 2026-01-23, a 9.1% gain. It stayed below the target. By 2026-04-10, it ended at $37.52. The thesis partly played out early, but it missed by the close.

What happened during the window

On 2026-02-03, MarketWatch reported that Novo Nordisk released fourth-quarter results early and gave a 2026 sales outlook below analyst expectations. On 2026-03-19, AP reported that the FDA approved a higher-dose Wegovy shot, with U.S. availability planned for April.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals